



Final Appraisal Recommendation

Advice No: 0320 – March 2020

Ketotifen (Ketofall®) 0.25mg/ml preservative-free eye drops

Limited submission by Scope Ophthalmics

Recommendation of AWMSG

Ketotifen (Ketofall®) is recommended as an option for restricted use within NHS Wales.

Ketotifen (Ketofall®) should be restricted within its licensed indication for the symptomatic treatment of seasonal allergic conjunctivitis, to the subpopulation of patients who require a preservative-free treatment.

Ketotifen (Ketofall®) is not recommended for use within NHS Wales outside of this subpopulation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3930), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0320:
Ketotifen (Ketofall®) strength formulation March 2020